Methadone and EDDP in Four Paired Vitreous–Blood Cases: Why the Table Matters More Than a Summary Ratio

Methadone and its metabolite EDDP need separate, specimen-specific interpretation after death. In four original laboratory cases reported by Brunet and Mura, both substances were lower in vitreous than in blood. The methadone table also showed more variability than the accompanying prose summary suggested.

What the four cases reported

The cases were investigated because methadone might have played a role in death. Methadone was detected in all four blood specimens. The authors described the blood concentrations as not lethal and stated that other causes of death could be advanced; they did not provide detailed individual causal determinations.

The report did not specify the anatomical blood collection site, individual postmortem intervals, case-specific storage history, doses or survival periods. These omissions prevent treating the four pairs as a uniform timing experiment.

The methadone summary did not capture every table value

Dividing vitreous by blood methadone gives approximately 0.43, 0.83, 0.09 and 0.18, respectively. Thus, the observed range calculated from the table is approximately 9–83%.

The prose instead describes vitreous methadone as 10–50% of blood. The difference matters particularly for case 5: 58 divided by 70 is approximately 83%, not 50% or less. The published table and summary should remain distinguishable rather than silently replacing one with the other.

Even an internally consistent four-case range would not validate a universal multiplier. These observations provide no independent prediction interval, antemortem comparison or controlled assessment of redistribution.

EDDP had a different pattern

The corresponding EDDP vitreous/blood quotients were approximately 0.24, 0.25, 0.20 and 0.20. In these observations, the metabolite’s relative concentrations varied less than the parent’s.

That descriptive finding does not establish a validated intake-timing rule. A parent drug and metabolite need not distribute alike, and their concentrations cannot be read as a simple clock without an appropriate kinetic study. The paper did not demonstrate one in these four people.

What did the analytical account establish?

The laboratory described matrix-matched vitreous calibration and centrifugation, alongside chromatographic screening and drug-analysis workflows. However, it did not provide a complete methadone/EDDP-specific numerical validation package for these paired results, including individual detection limits, quantitation limits and uncertainty.

The displayed concentrations therefore should retain the method information actually supplied. The historical review’s discussion of other laboratories’ screening devices or GC–MS confirmation does not establish that those procedures were used in these four original cases.

How to use the findings in a new case

The study supports the possibility of measurable methadone and EDDP in vitreous and demonstrates analyte-specific compartment differences. It does not justify concluding that a low vitreous value excludes important exposure or that a blood concentration can be recovered from a fixed ratio.

Neither drug detection nor the authors’ historical description of “nonlethal” blood values settles an individual cause of death. The broader vitreous-versus-blood screening evidence likewise requires the matrix, analyte and analytical limits to remain visible.

Primary source

Brunet B, Mura P. L’humeur vitrée en toxicologie médico-légale : revue de la littérature et applications [Vitreous humor as an alternative matrix in forensic toxicology: literature review and applications]. Annales de Toxicologie Analytique. 2012;24(1):9–15. doi:10.1051/ata/2012004. The case findings discussed here are the authors’ own laboratory observations within this review-and-applications paper.